TCWP’s Rhythm Pharmaceuticals RYTM Stock Holding History

TCWP’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-180	Closed	-$2K	–	1444
2022 Q1	$2K	Buy	+180	New	+$1.58K	﹤0.01%	1375

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

TCWP's RYTM Position: Q2 2022 in Review

TCWP sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2022, closing a stake of 180 shares — an estimated $2K sold.

TCWP first reported a position in RYTM in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 90 funds tracked by Wall St. Rank hold RYTM as of Q2 2022.

TCWP reported no remaining Rhythm Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
TCWP sold 180 Rhythm Pharmaceuticals shares in Q2 2022, an estimated $2K.
TCWP first reported a position in Rhythm Pharmaceuticals in Q1 2022 and held it in 1 quarter.
TCWP's Rhythm Pharmaceuticals position peaked at $2K in Q1 2022.
90 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.